InMed Pharmaceuticals Inc.
INM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $2 | $1 | $1 |
| % Growth | -37% | 40.9% | 13.5% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $1 |
| Gross Profit | $0 | $1 | $0 | $0 |
| % Margin | 36% | 44.2% | 13.9% | 41.5% |
| R&D Expenses | $1 | $0 | $1 | $1 |
| G&A Expenses | $2 | $3 | $1 | $2 |
| SG&A Expenses | $2 | $3 | $1 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $3 | $2 | $3 |
| Operating Income | -$2 | -$2 | -$2 | -$2 |
| % Margin | -157.5% | -137.1% | -167.7% | -198.5% |
| Other Income/Exp. Net | $0 | $0 | -$0 | -$0 |
| Pre-Tax Income | -$2 | -$2 | -$2 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$2 | -$2 | -$3 |
| % Margin | -154.2% | -137.1% | -168.1% | -231.6% |
| EPS | -436.69 | -1.22 | -2.77 | -5.24 |
| % Growth | -35,694.3% | 56% | 47.1% | – |
| EPS Diluted | -436.69 | -1.22 | -2.77 | -5.24 |
| Weighted Avg Shares Out | 0 | 2 | 1 | 1 |
| Weighted Avg Shares Out Dil | 0 | 2 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2 | -$2 | -$2 | -$2 |
| % Margin | -140.2% | -137.1% | -157.8% | -188.4% |